LFA-1 knockout inhibited the tumor growth and is correlated with treg cells
Ting Niu, Zhengyang Li, Yiting Huang, Yuxiang Ye, Yilong Liu, Zhi-Jin Ye, Lingbi Jiang, Xiaodong He, Lijing Wang, Jiangchao Li
Abstract
Abstract Cancer immunotherapy has been proven to be clinically effective in multiple types of cancers. Lymphocyte function-associated antigen 1 (LFA-1), a member of the integrin family of adhesion molecules, is expressed mainly on αβ T cells. LFA-1 is associated with tumor immune responses, but its exact mechanism remains unknown. Here, two kinds of mice tumor model of LFA-1 knockout (LFA-1 −/− ) mice bearing subcutaneous tumor and Apc Min/+ ;LFA-1 −/− mice were used to confirm that LFA-1 knockout resulted in inhibition of tumor growth. Furthermore, it also demonstrated that the numbers of regulatory T cells (Treg cells) in the spleen, blood, mesenteric lymph nodes were decreased in LFA-1 −/− mice, and the numbers of Treg cells in mesenteric lymph nodes were also decreased in Apc Min/+ ;LFA-1 −/− mice compared with Apc Min/+ mice. LFA-1 inhibitor (BIRT377) was administered to subcutaneous tumor-bearing LFA-1 +/+ mice, and the results showed that the tumor growth was inhibited and the number of Treg cells was reduced. The analysis of TIMER tumor database indicated that LFA-1 expression is positively associated with Treg cells and TNM stage. Conclusively, this suggests that LFA-1 knockout would inhibit tumor growth and is correlated with Treg cells. LFA-1 may be one potential target for cancer immunotherapy.